Racial and Ethnic Disparities in Established Cardiovascular Disease

Cardiovascular disease (CVD), including coronary artery disease, heart failure, and stroke, is the leading cause of death in the United States across every major racial and ethnic group. It is not, however, distributed evenly. Black adults carry the highest age-adjusted CVD mortality of any group tracked by national surveillance systems, develop hypertension roughly a decade earlier than white adults, and experience stroke at markedly higher rates in mid-life. Hispanic adults, as an aggregate group, show lower CVD mortality than non-Hispanic white adults despite higher rates of type 2 diabetes and obesity, a pattern researchers call the "Hispanic paradox." South Asian adults face substantially elevated coronary artery disease risk that current risk calculators and BMI thresholds do not fully capture. These are population-level patterns, not predictions for any individual patient, and several of the more specific numbers historically cited for this topic need primary-source verification before they should be treated as settled facts.

The useful clinical question is not simply "do disparities exist" (they do, and are well documented by the CDC and the American Heart Association) but which mechanism explains the gap for a given patient and population: mismeasured risk, unequal access to guideline-directed therapy, or unmeasured structural exposure. The answer changes what a clinician does next, and conflating the three leads to either fatalism or interventions aimed at the wrong lever.

What is established, and what still needs verification

Established from CDC and AHA national surveillance: Black Americans have higher age-adjusted CVD and stroke mortality than white Americans, and this gap is most pronounced in mid-life age bands rather than in older age. The CDC's stroke data show Black adults experiencing stroke at a markedly higher rate than white adults in the 45-to-64 age range (CDC Stroke Facts). The CDC's national diabetes surveillance likewise documents higher diabetes prevalence in Black and Hispanic adults than in white adults (CDC National Diabetes Statistics Report), which is a known amplifier of cardiovascular risk in every population.

Plausible but requiring primary-source confirmation before quoting a precise figure: Several statistics that circulate widely in cardiovascular equity writing, including specific percentage gaps in statin prescribing, revascularization rates, and trial-specific mortality reductions, trace back to individual studies (ALLHAT, A-HeFT, REGARDS, MESA, ORBIT-AF, and Medicare claims analyses) that this draft cannot verify against the original publication with confidence. The general direction of these findings, that Black and Hispanic patients with established ASCVD receive high-intensity statins, revascularization, and newer heart failure therapies less often than white patients with comparable disease, is consistent with a substantial published literature on cardiovascular treatment equity. The exact magnitude of any single gap should not be repeated as a precise number until the underlying study is checked and cited directly.

Not established: Whether the residual risk that persists in Black adults after adjusting for measured risk factors reflects unmeasured biology, unmeasured social exposure, or a mix of both is not settled science. Guideline bodies (AHA/ACC) treat race and ancestry as a risk-modifying signal for decision-making, not as a biological explanation, and this article follows that framing.

Black Americans: earlier onset, sustained pressure load

Black adults develop hypertension earlier and, on average, sustain higher blood pressure even after starting treatment, which over decades contributes to more hypertensive heart disease, left ventricular hypertrophy, heart failure with preserved ejection fraction, and hemorrhagic stroke. The CDC's age-stratified stroke data are the clearest, most directly verifiable evidence for this pattern: stroke incidence in Black adults aged 45 to 64 is substantially higher than in white adults in the same age band (CDC Stroke Facts). Because these deaths and disabling strokes cluster in decades when white peers are still largely free of clinical disease, aggregate mortality-ratio statistics understate the years of life and functional independence lost.

Large hypertension outcome trials from the 1990s and 2000s, most prominently ALLHAT, are widely cited as the evidence base for current guideline language favoring thiazide-type diuretics or long-acting calcium channel blockers as first-line agents in Black adults without heart failure or proteinuric chronic kidney disease. This recommendation is reflected in ACC/AHA hypertension guidance. Readers and clinicians should confirm the specific trial findings against the original JAMA publication rather than relying on secondary summaries, since the exact effect sizes attributed to this trial vary across sources.

Hispanic adults: a paradox with real limits

Hispanic adults as a group show lower aggregate CVD mortality than non-Hispanic white adults despite a higher prevalence of type 2 diabetes and obesity. This "Hispanic paradox" or "healthy immigrant effect" has been the subject of systematic review, and proposed explanations include selective migration of healthier individuals, strong social support networks, and dietary patterns in recent immigrant cohorts. The paradox is not uniform: Mexican-American adults carry a heavy burden of diabetes-related cardiovascular complications, and Puerto Rican adults do not show the same mortality advantage seen in other Hispanic subgroups. As immigrant cohorts age in the United States and acculturate, the mortality advantage tends to narrow. A population-level paradox should not reduce individual-level vigilance about risk-factor control.

South Asian and other Asian-American subgroups

Treating "Asian American" as a single cardiovascular risk category is a well-recognized error in this field. Adults of South Asian ancestry (India, Pakistan, Bangladesh, Sri Lanka, Nepal) are consistently described in the cardiology literature as facing several-fold higher coronary artery disease risk than non-Hispanic white adults, with earlier disease onset. The proposed mechanism involves insulin resistance, an atherogenic lipid pattern (small dense LDL, elevated lipoprotein(a)), and central adiposity occurring at body mass indexes that standard screening thresholds classify as normal. The specific citation most often used to support this claim in older summaries (a 1995 case-series style paper) is not a strong enough evidence anchor for a precise multiplier, and a current systematic review or a South Asian-specific cohort study should be located and cited directly before this article states an exact risk ratio. East Asian-American adults generally show lower CVD mortality than white Americans, though rising rates of metabolic syndrome with acculturation in some subgroups (for example, some Japanese-American and Korean-American cohorts) are reported in the literature and deserve their own verified sourcing.

Where the treatment gap lives

Even after accounting for insurance status and measured comorbidity burden, several categories of guideline-directed therapy show persistent differences in who receives them:

• Revascularization. Registry and claims-based analyses have reported that Black patients with obstructive coronary disease undergo percutaneous coronary intervention or bypass surgery less often than white patients with comparable angiographic disease, and that the gap is not fully explained by documented patient preference or hospital type. The specific percentage difference commonly cited for this finding needs to be checked against the source paper before being repeated as an exact number.
• Heart failure therapy. Sacubitril/valsartan and SGLT2 inhibitors (dapagliflozin, empagliflozin) carry Class I guideline recommendations for heart failure with reduced ejection fraction regardless of race. Post-approval prescribing data have reported lower initiation rates of these agents in Black patients relative to white patients, a gap worth tracking at the practice level even though this draft cannot certify the exact percentage from the original source.
• Atrial fibrillation anticoagulation. Black patients with atrial fibrillation have been reported to have higher stroke rates at equivalent CHA₂DS₂-VASc scores and lower rates of oral anticoagulation, including lower use of direct oral anticoagulants relative to white patients with similar bleeding-risk profiles.
• Statin therapy. The ACC/AHA cholesterol guideline recommends high-intensity statin therapy for all patients with established ASCVD regardless of race or ethnicity. Multiple claims-based analyses have reported lower high-intensity statin prescribing in Black adults with established ASCVD compared with white adults in the same nominal risk category, including within the same health system and insurance type. This is one of the more consistently replicated findings in the literature, though the exact percentage-point gap varies by dataset and should be sourced to the specific study before being quoted.

One clinically important and well-documented exception is BiDil (a fixed-dose combination of isosorbide dinitrate and hydralazine), which the FDA approved in 2005 specifically for self-identified Black adults with heart failure with reduced ejection fraction, based on the A-HeFT trial, which enrolled only Black participants. This remains a scientifically debated approval, because a single-race trial cannot determine whether the observed benefit is race-specific biology or reflects that the comparator arm was under-treated with standard ACE-inhibitor therapy at the time. Clinicians should understand BiDil as an FDA-approved, race-restricted indication with an unresolved mechanistic question behind it, not as proof that race predicts drug response in general.

Guideline positions on race and risk

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease lists South Asian ancestry, and conditionally Black race, among the "risk-enhancing factors" clinicians should weigh when a statin initiation decision is uncertain after calculating pooled cohort equation (PCE) risk. This is a guideline recommendation, not a claim about individual biology, and it exists precisely because the PCE, built on cohorts that underrepresented these groups, is known to misestimate risk at the margins for some populations.

The American Heart Association has published a presidential advisory (2020) and related scientific statements addressing structural racism as an upstream driver of cardiovascular health inequity, calling for standardized race and ethnicity data collection in cardiovascular registries and routine social-risk screening at CVD encounters. A prior version of this article included direct quotations attributed to that advisory and to the primary prevention guideline. Those quotations could not be verified against the primary document during this revision and have been removed and replaced with paraphrase; anyone citing exact guideline language should pull it directly from the published AHA or ACC/AHA source rather than from this summary.

The International Society on Hypertension in Blacks has historically recommended considering earlier antihypertensive treatment initiation in Black adults, reflecting the earlier onset of target-organ damage documented in this population; the exact blood-pressure threshold in current ISHIB guidance should be confirmed against the current version of that guideline, since thresholds in hypertension guidelines have shifted over time (including the 2017 ACC/AHA reclassification of hypertension itself).

A decision framework for closing gaps in an individual practice

The core clinical problem is that three different mechanisms produce the same visible outcome (a patient not on guideline-directed therapy), and each mechanism needs a different fix. The following decision rule is offered as a starting checklist for outpatient cardiology, primary care, or population-health teams; it is a practice framework, not a validated clinical instrument.

Step 1: Classify the gap before treating it. For any patient with established ASCVD, heart failure, or atrial fibrillation who is not on an indicated therapy, ask which of these three categories applies:

Step 2: Do not skip risk recalibration for South Asian or borderline-risk Black patients. If PCE-estimated 10-year risk falls in a range where the statin decision is genuinely uncertain (roughly 5 to 20 percent, per ACC/AHA guidance), coronary artery calcium scoring is a reasonable next step before deciding to withhold or add a statin, rather than defaulting to the PCE number alone.

Step 3: Address adherence barriers before escalating dose or assuming non-adherence is behavioral. Pill burden, co-pay costs, and mail-order pharmacy access are first-line interventions; attributing a persistently elevated LDL or blood pressure to "non-adherence" without checking these factors risks mislabeling a structural problem as a patient problem.

Step 4: Audit, don't assume. A referral-completion or prescribing-rate gap of a clinically meaningful size between racial or ethnic groups within the same practice, after basic risk-adjustment, warrants a quality-improvement review rather than an assumption that the gap reflects clinical appropriateness. Practices vary in what threshold they consider actionable; this is a process recommendation, not a validated statistical cutoff.

Step 5: Know the boundary of a single-race trial. BiDil is the clearest example: a therapy shown effective in a single-race trial answers a narrower question (does this combination work in this cohort) than the question clinicians often want answered (is the biology race-specific). Do not extrapolate a single-race trial result to claims about mechanism.

Stroke: a larger, earlier-onset gap

Stroke deserves separate attention because the age-at-onset difference is more pronounced than for coronary disease. CDC data show Black adults in the 45-to-64 age band experiencing stroke at a substantially higher rate than white adults in the same age group (CDC Stroke Facts). Studies designed specifically to examine racial differences in stroke incidence (the REGARDS study is the most frequently cited) have reported that excess stroke incidence in Black adults persists even after statistical adjustment for hypertension, diabetes, and atrial fibrillation, though the exact residual percentage from that study should be confirmed against the primary publication before being quoted as a fixed number.

After ischemic stroke, guideline-indicated secondary prevention includes antiplatelet or anticoagulant therapy as appropriate to stroke mechanism, blood pressure control, and statin therapy. Reports in the literature describe Black stroke survivors as less likely than white survivors to be discharged on the full package of indicated secondary-prevention therapies and less likely to complete early outpatient neurology follow-up; these access and follow-through gaps are a reasonable target for care-coordination interventions regardless of the exact percentage gap reported in any single study.

When to seek urgent care regardless of any of this

None of the population-level patterns above should slow a decision to seek emergency care. Chest pain, sudden weakness or numbness on one side of the body, sudden difficulty speaking or understanding speech, sudden severe headache, or sudden vision loss all warrant emergency evaluation immediately, independent of a patient's race, ethnicity, calculated risk score, or prior cardiovascular history.

Research gaps

Cardiovascular trials have historically underenrolled Black, Hispanic, and South Asian participants relative to their share of disease burden, which limits how confidently trial results generalize to these populations, particularly for newer drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists. Lipoprotein(a) testing, which may carry particular relevance for South Asian and Black patients given reported lipid pattern differences, remains underused across the health system generally. Polygenic risk scores built predominantly on European-ancestry genomic data are known to perform less accurately in African- and Hispanic-ancestry populations, raising a real risk that genomic risk tools could widen rather than narrow existing disparities if deployed without population-appropriate calibration and validation.

Frequently asked questions

References

1. Centers for Disease Control and Prevention. Stroke Facts. Available at: https://www.cdc.gov/stroke/data-research/facts-stats/index.html
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Available at: https://www.cdc.gov/diabetes/data/statistics-report/index.html

The trials, registries, and guideline documents named throughout this article (ALLHAT, A-HeFT, REGARDS, MESA, ORBIT-AF, the 2019 ACC/AHA primary prevention guideline, the AHA presidential advisory on structural racism, and related Medicare and claims-based analyses) are described from memory of the published literature and could not be linked to a verified primary source during this revision. An editor or clinical reviewer should locate and cite the specific paper before any exact percentage, effect size, or direct quotation from these sources is republished.